Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | GHSR | Q92847 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19363960 | 0.93 | MTNR1B (0.44) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL4839514 | 0.89 | MTNR1B (0.46) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL30429107 | 0.89 | MTNR1B (0.46) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL30645340 | 0.89 | MTNR1B (0.46) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL31032732 | 0.88 | MTNR1B (0.46) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL30428513 | 0.87 | MTNR1B (0.45) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL30558539 | 0.86 | MEN1 (0.50) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL18066403 | 0.86 | MEN1 (0.50) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL4664862 | 0.86 | MEN1 (0.50) | MTNR1BDRD1PRMT5WDR77DRD2 | |
| SCHEMBL12162581 | 0.86 | MTNR1B (0.48) | MTNR1BDRD1PRMT5WDR77DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
| EP-1458714-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051869-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | MTNR1B 621/4885DRD1 1500/4885PRMT5 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.